New

Medicine

ACTRAPID 100IU 10ML (PHILLIPS)

Login to view prices

SKU:

COLDA011

Description

ACTRAPID 100IU 10ML (PHILLIPS) is a fast-acting insulin solution used to manage blood sugar levels in individuals with diabetes mellitus. Manufactured by Novo Nordisk, this insulin is produced using recombinant DNA technology to ensure purity and consistency.(MedeCify)

Key Features:

• Rapid Onset: Begins to lower blood glucose levels approximately 30 minutes after subcutaneous injection.
• Duration of Action: Effect lasts for about 8 hours, making it suitable for controlling postprandial (after meal) blood sugar spikes.(Medicines.org.uk)
• Composition: Each milliliter contains 100 IU of human insulin, with a total of 1,000 IU per 10 ml vial. (European Medicines Agency (EMA))
• Administration: Injected subcutaneously, typically into the abdomen, thigh, or upper arm.
• Compatibility: Often used in combination with intermediate or long-acting insulins to provide comprehensive blood sugar control. (MYDAWA)

Usage Instructions:

• Dosage: Follow the dosage prescribed by your healthcare provider, as it varies based on individual needs and blood glucose monitoring.
• Injection Sites: Rotate injection sites to prevent lipodystrophy (changes in fat tissue).(1mg)
• Storage: Store unopened vials in the refrigerator between 2°C and 8°C. Once in use, the vial can be kept at room temperature for up to 28 days.

Precautions:

• Hypoglycemia Risk: Monitor for signs of low blood sugar, such as shaking, sweating, or confusion, especially during peak insulin action times.
• Medical Conditions: Inform your doctor if you have liver, kidney, or heart disease, as dosage adjustments may be necessary. (Main Website)
• Pregnancy and Breastfeeding: Consult your healthcare provider before use during pregnancy or while breastfeeding.

Side Effects:

• Common: Injection site reactions (redness, swelling), hypoglycemia.(1mg)
• Less Common: Lipodystrophy, allergic reactions.
• Rare: Severe allergic reactions; seek immediate medical attention if symptoms occur.

For more detailed information, refer to the European Medicines Agency’s product information.(European Medicines Agency (EMA))

Note: Always consult with a healthcare professional before starting or adjusting insulin therapy.